Navigation Links
Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
Date:4/23/2009

customers, partners and shareholders will view our products as synonymous with our Company. We want people to think of only 'Jiangbo' as we continue to improve our Company and expand our product line," concluded Mr. Cao.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and produc
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
2. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
3. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
4. New Directions in Angioedema: A Focus on Pathogenesis and Classification
5. Angiogenesis inhibitor improves brain tumor survival by reducing edema
6. CFO of Genesis Pharmaceuticals Gives Live Interview on Bloomberg TV Asia
7. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
8. Study sheds light on angiogenesis inhibitors, points to limitations, solutions
9. Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
10. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
11. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2
... 6 The Female Health Company,(Amex: FHC ) ... has,determined that the Premarket Approval Application (PMA) it submitted ... accepted for,review. The Center for Devices and Radiological Health ... The Female Health Company, Inc., The Female Health ...
... strength and resilience is a, legacy and a reminder to our ... ... came from., TOLEDO, Ohio, Feb. 6 In her ... -, http://www.authorhouse.com ), Oleta J. Warren shares the tragic story of how,her ...
... First Collaborative Platform to Integrate, Bio-Pharmaceutical Document ... Mass., Feb. 6 Tourtellotte Solutions, a ... bio-pharmaceutical industry, is,pleased to announce the general ... collaboration platform for complex document authoring,review and ...
... 6 Rural/Metro,Corporation (Nasdaq: RURL ) announces it ... December 31, 2007 before the opening of the stock,markets ... host a,conference call and webcast to discuss these results ... wishing to join the Company,s conference call should dial,(877) ...
... ST. LOUIS, Missouri, February 6 Mosby,s,Nursing ... system from,Elsevier, today announced the launch of ... robust collection of pediatric-specific,Web-based competencies, numbering over ... deliver evidence based medicine electronically to help,healthcare ...
... and Virtually Undetectable in a, Doctor,s Office; Omron Healthcare ... Ill., Feb. 6 Relatively unknown,to most consumers, morning ... the morning -- is a serious condition known to ... regular home,blood pressure monitoring, patients can start to take ...
Cached Medicine News:Health News:The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application 2Health News:'Putting the Medical Profession on Notice!': Widow Tells Tragic Story of How Her Husband Died Due to Misdiagnosis and Mistreatment 2Health News:Tourtellotte Solutions' Fusion DMC(TM) Unifies the World of Bio-Pharma Documents 2Health News:Mosby's Nursing Skills(TM) Launches New Pediatric Collection 2Health News:Mosby's Nursing Skills(TM) Launches New Pediatric Collection 3Health News:Dangerous Condition Underscores Importance of Home Blood Pressure Monitoring 2Health News:Dangerous Condition Underscores Importance of Home Blood Pressure Monitoring 3
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A low viscosity type of bone cement, intended for syringe or cement gun application....
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
Medicine Products: